fda takes tirzepatide off shortage list Compounders protest as removes FDA reviews decision to put

Sugar might give you quick energy but then you crash hard

Zero Appetite Mini Meals Guide

The dual mechanism of GLP-1 and GIP agonism in Tirzepatide is hypothesized to provide an additive metabolic advantage over Semaglutides GLP-1-only action

Oral semaglutide offers a dual benefitaddressing both glycemic control and cardiovascular risk.Martin Holst Lange, Executive Vice President for Development at Novo Nordisk, stated, These data reinforce the comprehensive set of health benefits of semaglutide, making it a strong option for healthcare professionals addressing the spectrum of metabolic and cardiovascular health.The SOUL trial confirmed the established safety and tolerability of oral semaglutide, with no new safety concerns identified and long-term safety data covering over 33 million patient years.Dr A.K

Liraglutide was approved without a CVOT (Cardiovascular Outcome Trial) because authorities accepted the results from the LEADER study, designed for superiority